Heron Therapeutics, Inc. (HRTX) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
HRTX Revenue Growth
Revenue Breakdown (FY 2025)
HRTX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
HRTX Revenue Analysis (2014–2025)
As of May 8, 2026, Heron Therapeutics, Inc. (HRTX) generated trailing twelve-month (TTM) revenue of $154.9 million, reflecting slight decline in growth of -0.5% year-over-year. The most recent quarter (Q4 2025) recorded $40.6 million in revenue, up 6.2% sequentially.
Looking at the longer-term picture, HRTX's 5-year compound annual growth rate (CAGR) stands at +11.8%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $154.9 million in 2025, representing a new all-time high.
Revenue diversification analysis shows HRTX's business is primarily driven by C I N V A N T I (68%), Z Y N R E L E F (27%), and S U S T O L (6%). With over half of revenue concentrated in C I N V A N T I, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including PACB (+5.0% YoY), PCRX (+4.6% YoY), and ACRS (-58.2% YoY), HRTX has underperformed the peer group in terms of revenue growth. Compare HRTX vs PACB →
HRTX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| HRTXCurrent | $155M | -0.5% | +11.8% | -1.6% | |
 PACB | $160M | +5.0% | +15.2% | -348.5% | |
 PCRX | $726M | +4.6% | +11.1% | 4.6% | |
 ACRS | $8M | -58.2% | +3.8% | -975.9% | |
 JAZZ | $4.3B | +9.2% | +12.5% | 5.3% | |
 MDGL | $958M | +256.8% | - | -31.3% |
HRTX Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $154.9M | +7.4% | $113.6M | 73.3% | $-2,538,000 | -1.6% |
| 2024 | $144.3M | +13.6% | $105.6M | 73.2% | $-11,528,000 | -8.0% |
| 2023 | $127.0M | +18.0% | $61.9M | 48.8% | $-110,615,000 | -87.1% |
| 2022 | $107.7M | +24.7% | $52.8M | 49.0% | $-174,658,000 | -162.2% |
| 2021 | $86.3M | -2.6% | $40.3M | 46.7% | $-217,828,000 | -252.3% |
| 2020 | $88.6M | -39.3% | $52.4M | 59.2% | $-228,163,000 | -257.4% |
| 2019 | $146.0M | +88.4% | $84.3M | 57.8% | $-210,694,000 | -144.3% |
| 2018 | $77.5M | +151.8% | $50.0M | 64.5% | $-183,937,000 | -237.4% |
| 2017 | $30.8M | +2305.6% | $26.2M | 85.1% | $-194,558,000 | -632.4% |
| 2016 | $1.3M | - | $1.2M | 97.3% | $-170,915,000 | -13363.2% |
See HRTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs HRTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare HRTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonHRTX — Frequently Asked Questions
Quick answers to the most common questions about buying HRTX stock.
Is HRTX's revenue growth accelerating or slowing?
HRTX revenue growth slowed to -0.5%, below the 5-year CAGR of +11.8%. TTM revenue is $155M. The deceleration marks a shift from historical growth rates.
What is HRTX's long-term revenue growth rate?
Heron Therapeutics, Inc.'s 5-year revenue CAGR of +11.8% reflects the variable expansion pattern. Current YoY growth of -0.5% is near this long-term average.
How is HRTX's revenue distributed by segment?
HRTX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.